Alzheimer's: Old Drug, New Hope
Where more celebrated treatments have disappointed, Myriad's 20-year-old Flurizan is being quickly pushed into a Phase 3 trial
By Catherine Arnst
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.